SAIP-SFDA Conflict Over a Supplement Brand Name

A Saudi company manufactured an immune-supplement, registered the mark with SAIP (Class 5) over 9 months. When seeking SFDA licensing, the name was refused for implying an untested medical benefit. They had already spent SAR 2M on marketing.

Legal memo to SFDA showing the name is descriptive, not therapeutic. Preparing secondary packaging with mitigating language. Coordination with a licensed physician to file confirmation of non-misleading status. Backup plan: registering a secondary marketing name to replace the original on failure.

SFDA accepted the middle approach: original name with a commitment to no explicit health claims in ads. The company retained 85% of prior marketing investment value and completed product launch in 4 months.